PE20181007A1 - Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue - Google Patents

Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue

Info

Publication number
PE20181007A1
PE20181007A1 PE2018000391A PE2018000391A PE20181007A1 PE 20181007 A1 PE20181007 A1 PE 20181007A1 PE 2018000391 A PE2018000391 A PE 2018000391A PE 2018000391 A PE2018000391 A PE 2018000391A PE 20181007 A1 PE20181007 A1 PE 20181007A1
Authority
PE
Peru
Prior art keywords
inhibitors
viral replication
dengue viral
solvates
mono
Prior art date
Application number
PE2018000391A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Pierre Jean-Marie Bernard Raboisson
Jean-François Bonfanti
Tim Hugo Maria Jonckers
Dorothee Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of PE20181007A1 publication Critical patent/PE20181007A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion refiere a derivados de indol mono di-sustituidos de formula (I), una de sus formas estereoisomericas, una de sus sales, solvatos o polimorfos farmaceuticamente aceptables que comprende un grupol indol mono o di-sustituido, donde dicho compuesto se selecciona a partir del grupo en el que: R1 es H, F, CH3, Cl o OCF3, R2 es F, Cl, OCH3 o H; R3 es H, CH3 o F. Refiere tambien una composicion farmaceutica que comprende un compuesto de formula (I), una de sus formas estereoisomericas, una de sus sales, solvatos o polimorfos farmaceuticamente aceptables junto a uno o mas excipientes, diluyentes o portadores farmaceuticamente aceptables. La presente invencion es util para el tratamiento del dengue.
PE2018000391A 2015-09-16 2016-09-15 Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue PE20181007A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15185522 2015-09-16
EP16163465 2016-04-01

Publications (1)

Publication Number Publication Date
PE20181007A1 true PE20181007A1 (es) 2018-06-26

Family

ID=56958913

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000391A PE20181007A1 (es) 2015-09-16 2016-09-15 Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue

Country Status (37)

Country Link
US (1) US10786484B2 (es)
EP (1) EP3350163B1 (es)
JP (2) JP7045984B2 (es)
KR (1) KR102676442B1 (es)
CN (1) CN108368044B (es)
AU (1) AU2016323535B2 (es)
CA (1) CA2996856C (es)
CL (1) CL2018000697A1 (es)
CO (1) CO2018003369A2 (es)
CR (1) CR20180214A (es)
CY (1) CY1122792T1 (es)
DK (1) DK3350163T3 (es)
EA (1) EA035679B1 (es)
EC (1) ECSP18020039A (es)
ES (1) ES2778431T3 (es)
HR (1) HRP20200408T1 (es)
IL (1) IL258031B (es)
JO (1) JO3633B1 (es)
LT (1) LT3350163T (es)
MA (1) MA42811B1 (es)
MD (1) MD3350163T2 (es)
ME (1) ME03674B (es)
MX (1) MX381632B (es)
MY (1) MY188347A (es)
NI (1) NI201800040A (es)
PE (1) PE20181007A1 (es)
PH (1) PH12018500569B1 (es)
PL (1) PL3350163T3 (es)
PT (1) PT3350163T (es)
RS (1) RS60039B1 (es)
SI (1) SI3350163T1 (es)
SM (1) SMT202000140T1 (es)
TW (1) TWI758256B (es)
UA (1) UA123672C2 (es)
UY (1) UY36904A (es)
WO (1) WO2017046258A1 (es)
ZA (1) ZA201801764B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
KR101818521B1 (ko) * 2011-11-16 2018-01-16 대우조선해양 주식회사 마이크로채널 열교환기용 2상 유체 공급장치 및 그 방법
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA127863C2 (uk) 2015-12-16 2024-01-31 Локсо Онколоджі, Інк. Сполуки, які можна застосовувати як інгібітори кінази
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX393586B (es) 2017-05-22 2025-03-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
WO2024178504A1 (en) * 2023-02-27 2024-09-06 Enveric Biosciences Canada Inc. Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
WO2003050295A2 (en) 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2006204917A1 (en) 2005-01-14 2006-07-20 Smithkline Beecham Corporation Indole derivatives for treating viral infections
EA200701669A1 (ru) 2005-02-09 2008-02-28 Мидженикс Инк. Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AP2010005480A0 (en) 2008-06-03 2010-12-31 Siga Technologies Inc Small molecule inhibitors for the treatment or prevention of denque virus infection.
CA2733554A1 (en) * 2008-08-18 2010-02-25 Yale University Mif modulators
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
JP5716205B2 (ja) * 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JP6030035B2 (ja) * 2013-09-27 2016-11-24 富士フイルム株式会社 蛍光観察装置、内視鏡システム及びプロセッサ装置並びに作動方法
KR102290189B1 (ko) * 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 b형 간염 치료용 의약으로서의 이의 용도
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子xia抑制劑之具有雜環p2'基團之巨環化合物
PL3201177T3 (pl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
NO2721243T3 (es) 2014-10-01 2018-10-20
EP3201176B1 (en) 2014-10-01 2018-12-12 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
WO2017167950A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
CR20180496A (es) 2016-03-31 2018-12-06 Univ Leuven Kath Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA036637B1 (ru) 2016-03-31 2020-12-02 Такеда Фармасьютикал Компани Лимитед Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
CN109069482B (zh) 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
UA123276C2 (uk) 2016-04-01 2021-03-10 Кайт Фарма, Інк. Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PE20200342A1 (es) 2017-05-22 2020-02-14 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX393586B (es) 2017-05-22 2025-03-24 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue

Also Published As

Publication number Publication date
UY36904A (es) 2017-03-31
DK3350163T3 (da) 2020-03-16
JO3633B1 (ar) 2020-08-27
HRP20200408T1 (hr) 2020-06-12
RS60039B1 (sr) 2020-04-30
CY1122792T1 (el) 2021-05-05
CN108368044B (zh) 2021-06-15
NI201800040A (es) 2018-07-24
EA035679B1 (ru) 2020-07-24
CL2018000697A1 (es) 2018-07-06
HK1258320A1 (en) 2019-11-08
KR102676442B1 (ko) 2024-06-18
AU2016323535A1 (en) 2018-03-08
SMT202000140T1 (it) 2020-05-08
MX381632B (es) 2025-03-12
TWI758256B (zh) 2022-03-21
EP3350163B1 (en) 2019-12-25
US20180256544A1 (en) 2018-09-13
IL258031A (en) 2018-05-31
CR20180214A (es) 2018-05-14
CA2996856C (en) 2023-08-01
LT3350163T (lt) 2020-04-10
WO2017046258A1 (en) 2017-03-23
JP2018528222A (ja) 2018-09-27
CO2018003369A2 (es) 2018-07-10
JP7045984B2 (ja) 2022-04-01
US10786484B2 (en) 2020-09-29
PH12018500569A1 (en) 2018-09-17
PH12018500569B1 (en) 2023-05-26
CN108368044A (zh) 2018-08-03
ES2778431T3 (es) 2020-08-10
ME03674B (me) 2020-10-20
JP2021193092A (ja) 2021-12-23
UA123672C2 (uk) 2021-05-12
MD3350163T2 (ro) 2020-06-30
ZA201801764B (en) 2021-04-28
MA42811B1 (fr) 2020-03-31
PT3350163T (pt) 2020-03-23
ECSP18020039A (es) 2018-04-30
MY188347A (en) 2021-12-02
EA201890723A1 (ru) 2018-08-31
EP3350163A1 (en) 2018-07-25
SI3350163T1 (sl) 2020-07-31
PL3350163T3 (pl) 2020-08-24
TW201722912A (zh) 2017-07-01
KR20180051563A (ko) 2018-05-16
AU2016323535B2 (en) 2021-02-18
CA2996856A1 (en) 2017-03-23
MA42811A (fr) 2018-07-25
IL258031B (en) 2021-03-25
MX2018003256A (es) 2018-11-09

Similar Documents

Publication Publication Date Title
PE20181007A1 (es) Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CO2018000660A2 (es) Compuestos derivados del (3β)-cholest-5-en-3-alquil-3-ol y (3β)-cholest-3-alquil-3-ol
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
MX394700B (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
UY35630A (es) Carboxamidas primarias como inhibidores de btk
UY34888A (es) Inhibidores del virus de la hepatitis c
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2017001884A2 (es) Polimorfos de selinexor
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY40872A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2017002034A1 (es) Nueva triterpenona c-3 con derivados de amida inversa c-17 como inhibidores de vih.
MX374383B (es) Derivados de carboxamida como inhibidores de smurf-1
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano